RH-PRIVÉ
RH Privé, the leading developer of eco luxury homes on the Costa del Sol, has called on the acclaimed design studio Pininfarina for an exclusive conceptual interior design project. With designs of some of the most iconic sports cars in the automotive history and outstanding architectural projects such as the majestic ICONIC tower in Dubai in his charge, this collaboration aims to further enhance the exclusivity and luxury of the developer's most exclusive development: Carat Sky Villas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806233462/en/
RH Privé unveils two of the world’s most desirable luxury penthouses in Costa del Sol. (Photo: RH Privé)
The penthouses are currently under construction, with delivery expected by the end of the year. In their initial conceptualization, the orientation of each dwelling has played a fundamental role, one ‘floating on the sea’ and the other ‘immersed in the mountains’. Each penthouse has been designed based on a well-differentiated conceptual theme: the first incorporates nautical motifs and the second is inspired by different wood textures, with the intention of integrating nature into the home.
“We are proud to partner with Pininfarina. Our union has allowed us not only to align our values, but also to share experiences, ideas and cultures to result in the project of two exclusive penthouses, unique in Spain”, says Guillermo Rodríguez, CEO of RH Privé.
Carat Sky Villas: a unique experience with sustainability as its core
Both penthouses belong to Carat Sky Villas and are strategically located in the majestic enclave of Reserva del Higuerón, where residents can enjoy the best views of the Mediterranean Sea from the Costa del Sol, as well as large open garden spaces alligned with nature.
Talking about sustainability, Carat Sky Villas stands out for its water saving system based on the reuse of rainwater, decalcification and hydro-efficient taps. It also stands out for its maximum energy efficiency model based on an aerothermal system, individual ventilation and the use of large windows to make the most of natural light. Besides, apart from recycling 70% of the construction materials, RH Privé guarantees respect for the biodiversity of the environment by planting native species in the landscaping design and reforesting the area surrounding the development.
In addition, the homes will benefit from the installation of the latest technology on the market, with a domotic system that allows the control of lighting, access and air conditioning, among many other functions, being able to control everything remotely at any time.
Interior design philosophy and superb amenities
In the heart of these penthouses, borders do not exist, overcoming limits and creating spaces for unique moments. The Sea plays a fundamental role in the design of the spaces. The floors are oriented towards the sea, creating spaces flooded with natural light and offering unforgettable sunsets. Thanks to the large windows, the line between indoors and outdoors is blurred, accentuating the sensation of floating above the sea provided by the infinity pool.
Carat’s welcomes you to the community in which only a select few can live. An excellent wellness area consisting of a salt cave, massage room, hammam, sauna and an indoor heated pool that completes the spa area. For the sportiest Carat offers a luxury gym equipped with Technogym machines, featuring its exclusive Christian Dior equipment. Owners can also enjoy the cinema room, a coworking area with sea views and an outdoor space consisting of an infinity pool, pool bar and solarium. But that's not all, as the promotion will feature a 5-star concierge service, allowing owners to forget about tedious chores.
Download the complete image asset of the interiors here.
About RH Privé
RH Privé is the leading real estate promoter in sustainable luxury development in Spain. After more than 30 years of success in Reserva del Higuerón, in the heart of Costa del Sol, the figures speak for themselves: more than 500 homes delivered, more than 200 under construction and more than 160 recently launched on the market. Always committed to eco-luxury development, each construction enjoys the unique stamp of RH Privé under ESG criteria. With a future full of new projects and ambitions, sustainability plays and will play a key role at the heart of the company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806233462/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom